Compare STRIDES PHARMA SCIENCE with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs PLETHICO PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE PLETHICO PHARMA STRIDES PHARMA SCIENCE/
PLETHICO PHARMA
 
P/E (TTM) x 14.8 -1.1 - View Chart
P/BV x 0.9 0.0 5,218.6% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   PLETHICO PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
PLETHICO PHARMA
Mar-14
STRIDES PHARMA SCIENCE/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,147395 290.5%   
Low Rs64231 2,051.1%   
Sales per share (Unadj.) Rs317.2604.4 52.5%  
Earnings per share (Unadj.) Rs7.832.5 24.2%  
Cash flow per share (Unadj.) Rs25.151.3 48.8%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.3473.6 57.9%  
Shares outstanding (eoy) m89.5034.08 262.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.80.4 799.7%   
Avg P/E ratio x114.06.6 1,737.9%  
P/CF ratio (eoy) x35.74.2 859.8%  
Price / Book Value ratio x3.30.5 724.8%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,0587,262 1,102.4%   
No. of employees `0002.5NA-   
Total wages/salary Rs m4,3411,596 272.0%   
Avg. sales/employee Rs Th11,325.8NM-  
Avg. wages/employee Rs Th1,731.4NM-  
Avg. net profit/employee Rs Th280.1NM-  
INCOME DATA
Net Sales Rs m28,39420,598 137.8%  
Other income Rs m941386 243.5%   
Total revenues Rs m29,33420,984 139.8%   
Gross profit Rs m3,9652,818 140.7%  
Depreciation Rs m1,540642 239.8%   
Interest Rs m1,9621,593 123.2%   
Profit before tax Rs m1,403969 144.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97-138 -70.3%   
Profit after tax Rs m7021,107 63.4%  
Gross profit margin %14.013.7 102.1%  
Effective tax rate %6.9-14.3 -48.5%   
Net profit margin %2.55.4 46.0%  
BALANCE SHEET DATA
Current assets Rs m24,83618,877 131.6%   
Current liabilities Rs m18,99311,896 159.7%   
Net working cap to sales %20.633.9 60.7%  
Current ratio x1.31.6 82.4%  
Inventory Days Days7136 197.5%  
Debtors Days Days113198 57.3%  
Net fixed assets Rs m34,2899,861 347.7%   
Share capital Rs m895341 262.7%   
"Free" reserves Rs m23,65112,331 191.8%   
Net worth Rs m24,54616,139 152.1%   
Long term debt Rs m15,5134,706 329.7%   
Total assets Rs m65,43733,146 197.4%  
Interest coverage x1.71.6 106.7%   
Debt to equity ratio x0.60.3 216.8%  
Sales to assets ratio x0.40.6 69.8%   
Return on assets %4.18.1 50.0%  
Return on equity %2.96.9 41.7%  
Return on capital %6.912.3 56.1%  
Exports to sales %021.4 0.0%   
Imports to sales %015.2 0.0%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs mNA3,136 0.0%   
Fx inflow Rs m15,6974,402 356.6%   
Fx outflow Rs m7353,184 23.1%   
Net fx Rs m14,9621,219 1,227.9%   
CASH FLOW
From Operations Rs m1,8712,437 76.7%  
From Investments Rs m5,826-6,265 -93.0%  
From Financial Activity Rs m-10,1572,490 -407.9%  
Net Cashflow Rs m-2,615-1,337 195.6%  

Share Holding

Indian Promoters % 27.7 82.7 33.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 4.3 879.1%  
FIIs % 8.6 5.5 156.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 7.5 345.3%  
Shareholders   56,241 10,665 527.3%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 1,921 Points Higher; Banking and Auto Stocks Witness Huge Buying(Closing)

Share markets in India jumped sharply today after Finance Minister Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Sep 20, 2019 03:35 PM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS